Skip to content
Markets News
Stocks1 min read

BioNTech, DualityBio Trial Shows Modest Breast Cancer PFS Gain

Makkler Newsroom
October 26, 2026 · Based on reporting by GlobeNewswire, finanzen.net

The Phase 3 study met its primary endpoint, but survival data were immature and the companies said the potential benefit may be limited.

Key takeaways

  • The trial showed a statistically significant but modest improvement in progression-free survival.
  • Most reported lung disease cases were Grade 1 or 2; severe and fatal cases occurred in a small proportion.

BioNTech and DualityBio said their Phase 3 DYNASTY-Breast02 trial met its primary endpoint, showing a statistically significant but modest improvement in progression-free survival with trastuzumab pamirtecan versus investigator-selected chemotherapy. The study involved chemotherapy-naïve patients with HR+/HER2-low metastatic breast cancer whose disease had progressed on endocrine therapy.

At an interim analysis, overall-survival data were not mature. The companies reported a higher rate of interstitial lung disease than in earlier trials; most cases were Grade 1 or 2, while severe and fatal events occurred in a small proportion.

The companies said data available at the cutoff suggest the potential benefit would be limited in the context of current treatment options. They will discuss the data and determine next steps.

Topics

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.